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Building on the discovery that MyoD expression reprograms fibroblasts into muscle, three papers
(Vierbuchen et al., 2010; Ieda et al., 2010; Szabo et al., 2010) recently reported the reprogramming of
fibroblasts into neurons, cardiomyocytes, and blood cell progenitors without first passing the cells
through a pluripotent state. Here we discuss the advantages and challenges of harnessing this
direct reprogramming method for regenerative medicine.How do cells in the body adopt and maintain specialized fates
such as that of a brain, heart, or blood cell? From developmental
biology, we know that embryonic stem cells (ESCs) gradually
progress from a multipotent state, capable of generating all line-
ages, to a highly specialized state by sequential restriction of
their differentiation potential. Indeed, this developmental para-
digmcanbe harnessed in vitro to direct humanESCs into a broad
range of specialized cell types in a stepwise manner (Murry and
Keller, 2008). However, in the 1960s John Gurdon and
colleagues made the surprising observation that the nucleus of
a differentiated frog cell, when transferred into an enucleated
egg, could be reprogrammed back to the totipotency of a zygote
and then give rise to awhole new frog (Gurdon, 2006). The poten-
tial applications of this nuclear reprogramming strategy became
obvious in 1996 with the birth of Dolly the sheep, the first
mammal cloned from an adult somatic cell.
Ten years before Dolly, though, pioneering studies by Harold
Weintraub and colleagues hinted that more direct routes to
lineage specification were possible. They demonstrated that
the expression of a single transcription factor, MyoD, is sufficient
to convert fibroblast cells and numerous other cell types into
skeletal muscle cells, completely bypassing normal develop-
mental lineage progression (Weintraub et al., 1989). Since
then, other remarkable examples of cell-fate reprogramming
by a single transcription factor have been reported, including
the ectopic induction of eyes on the legs of fruit flies by Pax6
expression, as reported by Walter Gehring (Halder et al., 1995).
However, the usefulness of these approaches for regenerative
medicine had remained largely neglected.
This all changed 5 years agowhen Takahashi and Yamanaka’s
landmark study (Takahashi and Yamanaka, 2006) demonstrated
that transcription factor-based reprogramming can achieve cell-
fate transitions comparable in scope to those observed in
nuclear transfer studies. Clearly, this induced pluripotent stem
cell (iPSC) technology has revolutionized the field of regenerative
medicine, triggering thousands of studies aimed at cell therapy,
disease modeling, and personalized medicine. However, if the
ultimate goal for translational medicine is to produce differenti-ated cell types on demand, is it indeed necessary to take an
iPSC ‘‘detour’’ back to pluripotency rather than directly program-
ming a differentiated cell fate as illustrated by the work of
Weintraub and Gehring? In 2008, Zhou et al. reported the first
example of transcription factor-based reprogramming in regen-
erative medicine by converting exocrine cells into insulin-
producing endocrine cells in the mouse pancreas in vivo. Now
three recent studies demonstrate that direct lineage program-
ming can yield a diverse range of medically relevant cell types,
such as neurons (Vierbuchen et al., 2010), cardiomyocytes
(Ieda et al., 2010), and blood cell progenitors (Szabo et al.,
2010). Here we discuss these recent studies in the context of
their potential future applications in regenerative medicine and
in contrast to the more established iPSC paradigm.
Transcription Factor-Based Reprogramming
of Fibroblasts
Takahashi and Yamanaka sought to find specific factors that,
when expressed in mouse embryonic fibroblasts, could repro-
gram the somatic cells into pluripotent stem cells (Figure 1)
(Takahashi and Yamanaka, 2006). Using retroviral vectors, they
expressed 24 candidate genes and selected for reprogrammed
cells by incorporating a neomycin resistance and b-galactosi-
dase reporter genes (i.e., bgeo) into Fbx15, a gene expressed
in but not essential for pluripotent stem cells. They then used
a reductive or ‘‘leave one out’’ strategy to determine the minimal
set of factors required for reprogramming fibroblasts into iPSCs.
Thus, the reprogramming cocktail of Oct4, Sox2, Klf4, and Myc
was defined. Since then, many important improvements have
been made to this iPSC technology (Hanna et al., 2010), but,
the original work by Takahashi and Yamanaka remains to date
the fundamental discovery that inspired the iPSC field. In addi-
tion, their findings also prompted researchers to start screening
for factor combinations that could direct lineage reprogramming.
In February 2010, Vierbuchen et al. (2010) reported a method
for reprogramming fibroblasts into excitatory neurons, called
‘‘iNs’’ for induced neurons (Figure 1). Using a strategy similar
to Takahashi and Yamanaka, the authors cloned 19 candidateCell 145, June 10, 2011 ª2011 Elsevier Inc. 827
Figure 1. Current Methods for Reprogramming Cell Fate
Schematic illustration of four recent studies that have successfully re-
programmed fibroblasts into pluripotent stem cells, neurons, cardiomyocytes,
and blood progenitors using ectopic expression of transcription factors.transcription factors into lentiviruses and then cotransduced the
factors into mouse embryonic fibroblasts isolated from a non-
neural region of a mouse embryo (E14.5). The cells expressed
enhanced green fluorescent protein (EGFP) under control of
the Tau locus; Tau is a microtubule-associated protein found
most abundantly in the central nervous system and, thus, can
be used to selectively identify neurons.
Starting with the 19-factor cocktail, the authors found fluores-
cent cells that also exhibited molecular hallmarks of neurons
(e.g., Tuj1, NeuN, MAP2, Synapsin, vGLUT) 12 days after trans-
duction. The reductive strategy reduced the cocktail to two
3-factor combinations: Ascl1, Brn2, and Mytl1 or Zic1. Extensive
electrophysiological studies convincingly demonstrated that the
iNs function as typical neurons in vitro.
Nevertheless, the study also left many questions unanswered.
For example, although the authors used a doxycycline-inducible
system to initiate reprogramming, they did not yet test the
stability of the reprogrammed iNs by withdrawing doxycycline.
Also, neither transplantations nor a global analysis of molecular
properties (e.g., gene expression, chromatin, proteomics) were
performed to better characterize iNs’ in vivo potential or in vitro
identity, respectively. Other critical questions for the field include
whether this approach is applicable to human cells and whether
modifying transcription factor cocktail will provide access to the
myriad of neuronal subtypes of the mammalian nervous system.
Six months after Vierbuchen et al.’s report, Ieda et al. (2010)
adapted and improved upon the basic strategy to generate828 Cell 145, June 10, 2011 ª2011 Elsevier Inc.induced cardiomyocytes (iCMs). This study used fibroblasts
frommultiple tissue sources (e.g., cardiac and tail-tip fibroblasts)
and included cell-fate mapping data and global gene expression
profiles. The study also compared the epigenetic status of the
reprogrammed iCMs to primary cardiomyocytes and cardiac
fibroblasts (Figure 1).
The authors initially tested a reprogramming cocktail of 14
genes encoding transcription factors related to heart develop-
ment. The fibroblasts for the primary screen were cardiac fibro-
blast-like cells (not expressing EGFP) isolated from heart
explants of transgenic mice expressing EGFP/puromycin under
a cardiac-specific alpha myosin heavy chain (aMHC) reporter.
Out of the initial pool of 14 factors, Gata4, Mef2c, and Tbx5
(T-box transcription factor) were found to optimally induce
the aMHC-GFP reporter (25% of cells) and cardiac Troponin T
(8% of cells).
The induced cardiomyocytes were stable for at least 1 week in
culture, even when the authors shut off the expression of the
three transcription factors. Furthermore, a subset of iCMs ex-
hibited spontaneous contractions and electrical activity in vitro,
particularly if the iCMs were derived from cardiac fibroblasts.
Next, the authors took the fibroblasts at an early stage of reprog-
ramming and injected them into the heart muscle of live animals.
These cells differentiated in situ and formed small isolated cardi-
omyocyte-like cells that were positive for the myofilament
marker a-actinin. However, only small numbers of iCMs were
observed in vivo, and it is not known whether these new inhabi-
tants of the heart were electrically coupled to endogenous cardi-
omyocytes. Finally, lineage-mapping experiments with inducible
reporters (i.e., Mesp-Cre/R26R-YFP and Isl1-Cre/R26R-YFP
reporter mice) suggested that the fibroblasts were directly re-
programmed to the iCM fate without evidence for an interme-
diate, mesoderm progenitor stage.
Szabo et al. (2010) reported that, unlike the direct reprogram-
ming observed with multitranscription factor cocktails, overex-
pression of a single factor (Oct4), in combination with exposure
to the cytokines SCF (stem cell factor) and FLT3LG (FMS-like
tyrosine kinase 3 ligand), reprograms a subset of human dermal
fibroblasts into CD45+/CD34+ hematopoietic progenitor colo-
nies (Figure 1). The resulting cells possess the potential to form
both erythroid and myeloid cells when exposed to the appro-
priate cytokines.
In the three previous studies, the key reprogramming factors
were known developmental regulators of the target cell lineage.
Thus, it was surprising that OCT4, as a single factor, could drive
blood lineage specification. Forced expression of Oct4 in adult
mice induced microscopic alterations in their epithelial cells
(i.e., epithelial dysplasia), likely because of progenitor cell
expansion; however, the authors found no evidence for epithelial
transformation into hematopoietic cells or any other ectopic
tissue phenotypes (Hochedlinger et al., 2005). Additionally,
Oct4 expression is not required for hematopoietic stem cell
maintenance, cell-fate determination, or general hematopoiesis
under steady-state conditions or competitive hematopoietic
reconstitution (Lengner et al., 2007). The authors proposed
that, despite its lack of expression during normal blood develop-
ment, OCT4 probably directly binds, and presumably activates,
hematopoietic-specific genes in induced blood precursors.
Box 1. A Roadmap for Directed Reprogramming Studies
(1) Identify cell of origin that is reprogrammed (clonal cultures)
(2) Define the minimal set of factors sufficient for reprogram-
ming (‘‘leave one out’’ experiments)
(3) Measure inductive efficiency (percent reprogrammed, cor-
rected for proliferation)
(4) Compare the molecular state of the induced cell to the
target cell (transcriptomic, epigenetic, proteomic)
(5) Measure functionality in vitro and in vivo (survival, integra-
tion, physiological response)
(6) Assess stability of reprogrammed cell fate (transgene inde-
pendence, nonintegrating vector)Independent of the mechanism, 100 putative hematopoietic
colonies were detected from 10,000 fibroblasts 21 days after
induction. These colonies were manually picked, and 34% of
them were shown to express the pan-hematopoietic marker
CD45 when treated with conditions favorable to hematopoietic
cells. Additionally, 25% of the cells within this CD45 com-
partment expressed the blood progenitor marker CD34.
In vitro exposure to hematopoietic cytokines stimulated the
formation of myeloid and erythroid cells (i.e., myelopoiesis
and erythropoiesis), although the authors found no evidence
for lymphopoiesis. Lineage specification was not examined at
the clonal level, and thus, it is difficult to assess whether the
induced hematopoietic progenitors were truly multipotent blood
precursors.
When the authors injected the CD45+ cells from Oct4-ex-
pressing fibroblasts directly into the femur of mice, they
observed low levels (<1%) of human chimerism and CD45
expression in the bone marrow of the mice (NOD/SCID IL2Rg
null mice) 10 weeks after injection. The authors interpret these
in vivo findings in a positive light, asserting that the induced
blood progenitor cells appear to lack leukemic or tumorigenic
stem cell properties. However, limited engraftment capabilities
and a bias for producing myeloid cells are also common prob-
lems observed in hematopoietic precursors derived from human
pluripotent stem cells (Murry and Keller, 2008). In fact, one inter-
pretation of Szabo and colleagues’ findings is that Oct4, in a
particular context, can partially reprogram fibroblasts toward
an unstable near-pluripotent state capable of differentiating
along blood lineages in the presence of hematopoietic cyto-
kines. Such a model fits with recent data from Kim et al. (2011)
in which neural progenitor cells were induced from mouse fibro-
blasts that underwent intermediate reprogramming toward
pluripotency followed by exposure to cell culture conditions
favorable for neural precursor cells.
A Roadmap for Directed Cell-Fate Reprogramming
The various findings on iNs, iCMs, and induced blood progeni-
tors raise the question of whether there is a common roadmap
for evaluating current directed reprogramming studies and
planning future ones (Box 1). The first question is which exact
cell is being reprogrammed? In many cases, fibroblast cultures
are isolated from heterogeneous tissues, such as a skin biopsy,
heart outgrowth cultures, and neonatal or adult tail-tip cultures.
To define more rigorously the cell of origin of a successful re-
programming event, clonal isolation of the starting cells should
represent a standard in future studies.
A second step is determining the minimum factors required for
reprogramming toward a target cell fate. Most studies to date
have used a reductive strategy to whittle down the number of
factors required for the minimally sufficient set. This is an impor-
tant point nicely illustrated by both Ieda et al. and Vierbuchen
et al., who both found that minimizing the number of factors
increased the overall reprogramming efficiency.
Third, what is the efficiency of reprogramming and what is the
best way to measure it? Estimates of reprogramming efficiency
can over- or underestimate the value depending on selective
culture conditions, picking method, or continued proliferation of
non-reprogrammed fibroblasts. Vierbuchen and colleagues at-tempted to address this issue by including bromodeoxyuridine-
incorporation studies to compensate for the discrepancy in
proliferation between fibroblasts and postmitotic neurons.
Another question is, how closely do reprogrammed cells
resemble their target cell counterparts? This question goes
back to the original observations by Weintraub and colleagues
showing that, for multiple starting cell populations, MyoD can
induce a myogenic program without suppressing the original
cell fate. The reprogrammed nerve cells coexpressed both
neural and muscle markers, and melanoma cells reprogrammed
with MyoD still produced pigment (Weintraub et al., 1989). In the
context of human iPSCs, a broad survey of their global molecular
state revealed that, despite their pluripotency, these cells may
not be identical to human ESCs. Thus, there may exist multiple
pluripotent states, and an iPSC may also retain molecular traces
of its cell of origin (Ohi et al., 2011). In the context of regenerative
medicine, it remains unclear how close these reprogrammed
cells need to be to provide adequate cell types for therapeutic
applications without increasing the risk of tumor formation or
other aberrant cell behaviors.
A fifth major question is whether all characteristics of the re-
programmed cell are faithfully maintained upon withdrawal of
the inducing factors. Experiments that used either DNA excision
or nonintegrating gene delivery have demonstrated that, for
many passages, iPSCs maintain expression of pluripotent
markers, differentiation capacity, and epigenetic state in the
absence of reprogramming factors (Hanna et al., 2010). This
stability is likely due to the induction of the intrinsic feedforward
network of factors controlling pluripotency (Boyer et al., 2005). It
is still unknown whether similar intrinsic gene expression
networks exist for differentiated cell types and whether these
networks are triggered during directed reprogramming. Indeed,
the answer may vary among different cell types. The complete
removal of reprogramming factors, by either excision of the viral
genome or the use of nonintegrating strategies (vectors or small
molecule), is an important next experiment for addressing these
questions in the reprogrammed cell types.
Finally, the most critical question for translational applications
is, how well do reprogrammed cells survive, integrate, and
respond to physiological cues both in vitro and in vivo? For
example, can iNs send and receive synaptic input upon trans-
plantation? Can iCMs efficiently integrate into a damaged heart
and truly contribute to its function?Cell 145, June 10, 2011 ª2011 Elsevier Inc. 829
Applications of Transcription Factor-Based
Reprogramming
For translational applications, it is particularly important to
consider the advantages and disadvantages of direct reprog-
ramming in comparison to the use of iPSC-derived cell types
(Table S1). iPSC technology has rapidly become the method of
choice for modeling human genetic disease and for subsequent
drug-screening efforts (see Minireview by R. Dolmetsch and
D.H. Geschwind on page 831 of this issue). iPSCs offer greater
scalability and flexibility, and multiple cell types relevant to
particular symptoms can be derived from a single iPS cell clone.
In addition, rapid progress has been made in using small mole-
cules and protein factors to direct iPSC fate specification,
enabling high-efficiency derivation of many lineages following
a modular developmental blueprint (Chambers et al., 2009). On
the other hand, it may be only a matter of time before directed
reprogramming can match the cell-type diversity currently
accessible only through a pluripotent intermediate.
One major weakness of iPSCs, which may be circumvented
by direct reprogramming, is the age of the resulting target tissue.
When starting with pluripotent cells, current protocols yield
differentiated cells that appear to correspond to fetal stages of
human development. This is a considerable challenge in the
context of modeling late-onset human diseases such as Alz-
heimer’s or Parkinson’s diseases (Saha and Jaenisch, 2009).
One intriguing question is whether direct reprogramming will
similarly reset developmental timing or whether the age of the
fibroblast will impact the age of the target cells obtained. Another
potential advantage of direct reprogramming is the overall speed
and simplicity of the differentiation conditions. In contrast,
disease modeling using iPSCs requires time to generate,
expand, characterize, and differentiate pluripotent cells.
The ultimate goal of regenerative medicine is to translate
discoveries from the research lab to the clinic, and unfortunately,
neither iPSC programming nor direct reprogramming is without
pitfalls. Tumor formation remains an important concern for
both approaches. Although the transition through an iPSC leads
to an additional risk of teratoma formation, both methods carry
other challenges, such as incomplete reprogramming, tissue-
inappropriate differentiation, or insertional mutagenesis caused
by the reprogramming factors. Recent gene therapy trials have
illustrated that the latter is indeed a serious concern for clinical
translation. Directed reprogramming approaches will likely
require convertingmillions of fibroblasts, which greatly increases
the risk of an adverse insertional event, whereas clonal iPSC
cultures could be either screened for integration into ‘‘safe
harbor’’ sites (Papapetrou et al., 2011) or established and differ-
entiated without any genetic modification. Finally, one attractive
therapeutic strategy that is unique to direct reprogramming is
the in situ conversion of cell fate. This approach was pioneered
by Zhou et al. in 2008 when they used transcription factors
to convert exocrine cells to insulin-producing endocrine
lineages in the pancreas of mouse (Zhou et al., 2008). Thus,
the effective in situ conversion of fibroblasts into cardiomyocytes
or neurons in patients following heart or brain injury, respectively,
seems like science fiction today but may well become an impor-
tant therapeutic strategy for the future.830 Cell 145, June 10, 2011 ª2011 Elsevier Inc.Just a few years ago, no good options were available for
generating genetically matched tissues for cell therapy or
human disease modeling, and researchers were struggling to
realize the potential of nuclear transfer-based reprogramming
strategies. Today, we have at least two major options, both
of which may be generally applicable for future therapeutic
studies. Although iPSC technology currently has the upper
hand in producing therapeutically relevant cell types, we should
not forget that in the context of regenerative medicine, iPSCs
had a ‘‘head-start’’ of nearly 5 years. Directed reprogramming
studies should be able to co-opt the various technical strate-
gies developed for iPSC research in an effort to overcome
many of the technical challenges discussed here. Ultimately,
the usefulness of directed reprogramming will depend on ex-
panding our basic understanding of the complexity and subtle-
ties required to drive an authentic cell fate across a distant
lineage boundary.
SUPPLEMENTAL INFORMATION
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